Aβ-Amyloid deposition in patients with parkinson disease at risk for development of dementia

Myria Petrou, Nicolaas I. Bohnen, Martijn L T M Müller, Robert A. Koeppe, Roger L. Albin, Kirk A. Frey

Research output: Contribution to journalArticle

Abstract

Objective: The aim of our study was to examine the relationship between corticostriatal Aβ- amyloid deposition and cognitive dysfunction in a cohort of patients with Parkinson disease (PD) at risk for dementia. Methods: This was a cross-sectional study of 40 patients with PD with mild cognitive impairment (MCI) or other known dementia risk factors. Subjects underwent dynamic Aβ-amyloid and vesicular monoamine transporter 2 PET imaging using [11C] Pittsburgh compound B (PiB) and [11C] dihydrotetrabenazine (DTBZ), respectively, and neuropsychological assessment. PiB and DTBZ PET data were analyzed using the Logan graphical method to determine cerebral PiB deposition relative to the cerebellar hemispheres and striatal DTBZ binding relative to occipital neocortex. Component z scores were calculated for individual cognitive domains (memory, visuospatial processing, working memory/attention, and executive function) and combined linearly for global estimation of cognition. Correlation of cognitive function and cortical PiB binding was investigated. Results: Elevated cerebral PiB binding at levels seen in patients with AD was infrequent (6 of 40 subjects). Mean cortical PiB binding in the entire cohort was 1.16 ± 0.16 (distribution volume ratio; range 0.96-1.78). A significant correlation was noted between cortical PiB binding and global composite cognitive function (r=-0.55, p <0.005) as well as the Wechsler Adult Intelligence Scale score (r=-0.54, p = 0.0004). Conclusion: Elevated cerebral A-amyloid deposition at levels seen in Alzheimer disease is uncommon in subjects with PD at risk for dementia. In our sample, the prevalence of markedly elevated PiB binding was significantly lower than that found in prior studies of cognitively normal elderly individuals. Neocortical PiB binding correlated robustly with measures of cognitive impairment in our cohort.

Original languageEnglish (US)
Pages (from-to)1161-1167
Number of pages7
JournalNeurology
Volume79
Issue number11
DOIs
StatePublished - Sep 11 2012

Fingerprint

Amyloid
Parkinson Disease
Dementia
Cognition
Vesicular Monoamine Transport Proteins
2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole
Pittsburgh
Parkinson's Disease
Deposition
Corpus Striatum
Neocortex
Executive Function
Intelligence
Short-Term Memory
Alzheimer Disease
Cross-Sectional Studies

ASJC Scopus subject areas

  • Clinical Neurology
  • Arts and Humanities (miscellaneous)

Cite this

Petrou, M., Bohnen, N. I., Müller, M. L. T. M., Koeppe, R. A., Albin, R. L., & Frey, K. A. (2012). Aβ-Amyloid deposition in patients with parkinson disease at risk for development of dementia. Neurology, 79(11), 1161-1167. https://doi.org/10.1212/WNL.0b013e3182698d4a

Aβ-Amyloid deposition in patients with parkinson disease at risk for development of dementia. / Petrou, Myria; Bohnen, Nicolaas I.; Müller, Martijn L T M; Koeppe, Robert A.; Albin, Roger L.; Frey, Kirk A.

In: Neurology, Vol. 79, No. 11, 11.09.2012, p. 1161-1167.

Research output: Contribution to journalArticle

Petrou, M, Bohnen, NI, Müller, MLTM, Koeppe, RA, Albin, RL & Frey, KA 2012, 'Aβ-Amyloid deposition in patients with parkinson disease at risk for development of dementia', Neurology, vol. 79, no. 11, pp. 1161-1167. https://doi.org/10.1212/WNL.0b013e3182698d4a
Petrou M, Bohnen NI, Müller MLTM, Koeppe RA, Albin RL, Frey KA. Aβ-Amyloid deposition in patients with parkinson disease at risk for development of dementia. Neurology. 2012 Sep 11;79(11):1161-1167. https://doi.org/10.1212/WNL.0b013e3182698d4a
Petrou, Myria ; Bohnen, Nicolaas I. ; Müller, Martijn L T M ; Koeppe, Robert A. ; Albin, Roger L. ; Frey, Kirk A. / Aβ-Amyloid deposition in patients with parkinson disease at risk for development of dementia. In: Neurology. 2012 ; Vol. 79, No. 11. pp. 1161-1167.
@article{d7a8d100f98549a88aa3f27594d21c1d,
title = "Aβ-Amyloid deposition in patients with parkinson disease at risk for development of dementia",
abstract = "Objective: The aim of our study was to examine the relationship between corticostriatal Aβ- amyloid deposition and cognitive dysfunction in a cohort of patients with Parkinson disease (PD) at risk for dementia. Methods: This was a cross-sectional study of 40 patients with PD with mild cognitive impairment (MCI) or other known dementia risk factors. Subjects underwent dynamic Aβ-amyloid and vesicular monoamine transporter 2 PET imaging using [11C] Pittsburgh compound B (PiB) and [11C] dihydrotetrabenazine (DTBZ), respectively, and neuropsychological assessment. PiB and DTBZ PET data were analyzed using the Logan graphical method to determine cerebral PiB deposition relative to the cerebellar hemispheres and striatal DTBZ binding relative to occipital neocortex. Component z scores were calculated for individual cognitive domains (memory, visuospatial processing, working memory/attention, and executive function) and combined linearly for global estimation of cognition. Correlation of cognitive function and cortical PiB binding was investigated. Results: Elevated cerebral PiB binding at levels seen in patients with AD was infrequent (6 of 40 subjects). Mean cortical PiB binding in the entire cohort was 1.16 ± 0.16 (distribution volume ratio; range 0.96-1.78). A significant correlation was noted between cortical PiB binding and global composite cognitive function (r=-0.55, p <0.005) as well as the Wechsler Adult Intelligence Scale score (r=-0.54, p = 0.0004). Conclusion: Elevated cerebral A-amyloid deposition at levels seen in Alzheimer disease is uncommon in subjects with PD at risk for dementia. In our sample, the prevalence of markedly elevated PiB binding was significantly lower than that found in prior studies of cognitively normal elderly individuals. Neocortical PiB binding correlated robustly with measures of cognitive impairment in our cohort.",
author = "Myria Petrou and Bohnen, {Nicolaas I.} and M{\"u}ller, {Martijn L T M} and Koeppe, {Robert A.} and Albin, {Roger L.} and Frey, {Kirk A.}",
year = "2012",
month = "9",
day = "11",
doi = "10.1212/WNL.0b013e3182698d4a",
language = "English (US)",
volume = "79",
pages = "1161--1167",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Aβ-Amyloid deposition in patients with parkinson disease at risk for development of dementia

AU - Petrou, Myria

AU - Bohnen, Nicolaas I.

AU - Müller, Martijn L T M

AU - Koeppe, Robert A.

AU - Albin, Roger L.

AU - Frey, Kirk A.

PY - 2012/9/11

Y1 - 2012/9/11

N2 - Objective: The aim of our study was to examine the relationship between corticostriatal Aβ- amyloid deposition and cognitive dysfunction in a cohort of patients with Parkinson disease (PD) at risk for dementia. Methods: This was a cross-sectional study of 40 patients with PD with mild cognitive impairment (MCI) or other known dementia risk factors. Subjects underwent dynamic Aβ-amyloid and vesicular monoamine transporter 2 PET imaging using [11C] Pittsburgh compound B (PiB) and [11C] dihydrotetrabenazine (DTBZ), respectively, and neuropsychological assessment. PiB and DTBZ PET data were analyzed using the Logan graphical method to determine cerebral PiB deposition relative to the cerebellar hemispheres and striatal DTBZ binding relative to occipital neocortex. Component z scores were calculated for individual cognitive domains (memory, visuospatial processing, working memory/attention, and executive function) and combined linearly for global estimation of cognition. Correlation of cognitive function and cortical PiB binding was investigated. Results: Elevated cerebral PiB binding at levels seen in patients with AD was infrequent (6 of 40 subjects). Mean cortical PiB binding in the entire cohort was 1.16 ± 0.16 (distribution volume ratio; range 0.96-1.78). A significant correlation was noted between cortical PiB binding and global composite cognitive function (r=-0.55, p <0.005) as well as the Wechsler Adult Intelligence Scale score (r=-0.54, p = 0.0004). Conclusion: Elevated cerebral A-amyloid deposition at levels seen in Alzheimer disease is uncommon in subjects with PD at risk for dementia. In our sample, the prevalence of markedly elevated PiB binding was significantly lower than that found in prior studies of cognitively normal elderly individuals. Neocortical PiB binding correlated robustly with measures of cognitive impairment in our cohort.

AB - Objective: The aim of our study was to examine the relationship between corticostriatal Aβ- amyloid deposition and cognitive dysfunction in a cohort of patients with Parkinson disease (PD) at risk for dementia. Methods: This was a cross-sectional study of 40 patients with PD with mild cognitive impairment (MCI) or other known dementia risk factors. Subjects underwent dynamic Aβ-amyloid and vesicular monoamine transporter 2 PET imaging using [11C] Pittsburgh compound B (PiB) and [11C] dihydrotetrabenazine (DTBZ), respectively, and neuropsychological assessment. PiB and DTBZ PET data were analyzed using the Logan graphical method to determine cerebral PiB deposition relative to the cerebellar hemispheres and striatal DTBZ binding relative to occipital neocortex. Component z scores were calculated for individual cognitive domains (memory, visuospatial processing, working memory/attention, and executive function) and combined linearly for global estimation of cognition. Correlation of cognitive function and cortical PiB binding was investigated. Results: Elevated cerebral PiB binding at levels seen in patients with AD was infrequent (6 of 40 subjects). Mean cortical PiB binding in the entire cohort was 1.16 ± 0.16 (distribution volume ratio; range 0.96-1.78). A significant correlation was noted between cortical PiB binding and global composite cognitive function (r=-0.55, p <0.005) as well as the Wechsler Adult Intelligence Scale score (r=-0.54, p = 0.0004). Conclusion: Elevated cerebral A-amyloid deposition at levels seen in Alzheimer disease is uncommon in subjects with PD at risk for dementia. In our sample, the prevalence of markedly elevated PiB binding was significantly lower than that found in prior studies of cognitively normal elderly individuals. Neocortical PiB binding correlated robustly with measures of cognitive impairment in our cohort.

UR - http://www.scopus.com/inward/record.url?scp=84867510729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867510729&partnerID=8YFLogxK

U2 - 10.1212/WNL.0b013e3182698d4a

DO - 10.1212/WNL.0b013e3182698d4a

M3 - Article

VL - 79

SP - 1161

EP - 1167

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 11

ER -